⚠ Unsupported Browser ⚠
Our site probably won't work so great in Internet Explorer. Please try a more recent version of a major browser
like Chrome, Firefox, Safari, or Edge.
The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Trial
The FIELD Trial led by Prof. Anthony Keech, evaluated 9795 adults with Type 2 diabetes taking for an average of 5-years fenofibrate (a blood fat lowering tablet) or placebo (inactive tablet). Whilst the primary cardiovascular end-point of the trial was not positive there were cardiovascular benefits for some subgroups, such as those with high triglyceride / low HDL-C levels. On a very positive note, fenofibrate had major benefits to prevent lower limb amputations, to retard the development of sight-threatening diabetic eye damage and of diabetic kidney and nerve damage. Ongoing studies are evaluating the relationship of many novel biochemical and molecular risk factors to health outcomes for people with Type 2 diabetes. Ongoing research includes evaluating the value of novel blood tests (biomarkers) such as telomeres, lipidomics, proteomics, microRNAs and mRNAs.
Uric Acid Predicts Long‐Term Cardiovascular Risk in Type 2 Diabetes but Does Not Mediate the Benefits of Fenofibrate: the FIELD Study.
2020 Diabetes, Obesity and Metabolism
Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study.
2018 The Lancet Diabetes and Endocrinology
Low alanine aminotransferase levels and higher number of cardiovascular events in people with Type 2 diabetes: analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
2015 Diabetic Medicine
Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study.
Serum 25-Hydroxyvitamin D: A Predictor of Macrovascular and Microvascular Complications in Patients With Type 2 Diabetes.
2015 Diabetes Care
Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
HDL-C and HDL-C/ApoA-I Predict Long-Term Progression of Glycemia in Established Type 2 Diabetes.
2014 Diabetes Care
Benefits and Safety of Long-Term Fenofibrate Therapy in People With Type 2 Diabetes and Renal Impairment.
2012 Diabetes Care
Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study.